Eltrombopag - a novel approach for the treatment of chronic immune thrombocytopenic purpura: Review and safety considerations

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 139-145

  Cook, Lucy ^a   Cooper, Nichola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Eltrombopag; Immune thrombocytopenic purpura; Thrombopoietin

Indexed keywords

ANTACID AGENT; CALCIUM; ELTROMBOPAG; PEGYLATED RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANTIBODY PRODUCTION; BLEEDING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MYELOFIBROSIS; PANCYTOPENIA; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; QUALITY OF LIFE; REBOUND; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANIMAL; CHRONIC DISEASE; DRUG EFFECT; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE;

ANIMALS; BENZOIC ACIDS; BLOOD PLATELETS; CHRONIC DISEASE; HUMANS; HYDRAZINES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79952031932     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/dddt.s8601     Document Type: Review

References (46)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
2. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1369.
3. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.
4. Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974-980.
5. Houwerzijl EJ, Blom NR, van der Want JJ, Vellenga E, de Wolf JT. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia. 2006;20(11):1937-1942.
6. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
7. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574-596.
8. Kimura H, Ishibashi T, Shikama Y, et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood. 1990;76(12):2493-2500.
9. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77(7):1117-1124.
10. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91(23):11104-11108.
11. Metcalf D, Burgess AW, Johnson GR, et al. In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF. J Cell Physiol. 1986;128(3):421-431.
12. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood. 1986;68(1):46-57.
13. Carver-Moore K, Broxmeyer HE, Luoh SM, et al. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood. 1996;88(3):803-808.
14. Gainsford T, Roberts AW, Kimura S, et al. Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood. 1998;91(8):2745-2752.
15. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009;60:193-206.
16. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999;94(4):1273-1282.
17. Yang C, Li YC, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol. 1999;105(2):478-485.
18. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996;87(2):567-573.
19. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87(10):4068-4071.
20. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996;93(3):704-706.
21. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336(6):404-409.
22. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002;99(7):2599-2602.
23. Komatsu N, Okamoto T, Yoshida T, et al. Pegylated recombinant human megakaryocyte growth and development factor (PEGrHuMGDF) increased platelet counts (PLT) in patients (pts) with aplastic anemia (AA) and myelodyplastic syndrome (MDS). Blood. 2000;96(11):1273.
24. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997;126(9):673-681.
25. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000;132(5):364-368.
26. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;95(8):2530-2535.
27. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebocontrolled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89(9): 3118-3128.
28. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000;18(15):2852-2861.
29. Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999;93(9):2798-2806.
30. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood. 2002;100(2):728-730.
31. Li JZ, Yang C, Xia YP, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241-3248.
32. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem. 2001;44(22):3730-3745.
33. Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho 1,2-d imidazole thrombopoietin mimics. J Med Chem. 2002;45(17):3576-3578.
34. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005;33(1):85-93.
35. Jenkins JM, Williams D, Deng YL, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109(11):4739-4741.
36. Bussel JB, Cheng G, Kovaleva L, et al. Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study. Blood (ASH Annual Meeting Abstracts). 2007;110(11):566.
37. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641-648.
38. Weili Bao SH, Karpoff M, Bussel JB, Yazdanbakhsh K. Improved Regulatory T Cell Activity in Patients with Chronic Immune Thrombocytopenia Purpura Treated with Thrombopoietic Agents 51st ASH annual meeting and exposition. Ernest N. Morial Convention Center, New Orleans, LA. 2009;684:279-282.
39. Grotzinger KM, Johnson FR, Hauber AB, Ozdemir S, Bala MV. Patients are willing to trade off efficacy, safety, and administration attributes of chronic Idiopathic Purpura (ITP) therapy: Results from a large North American discrete choice study. Blood (ASH Annual Meeting Abstracts). 2008;112(11):669.
40. Bussel JB, Marks KM. How effective is eltrombopag for the treatment of thrombocytopenia in patients with HCV infection? Nat Clin Pract Gastroenterol Hepatol. 2008;5(8):424-425.
41. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol. 2009;37(9):1030-1037.
42. Ghulam Mufti AB, Robert Hasserjian, Barbara Bain, David Kuter, Lyndah Dreiling, Janet Nichol. Bone marrow reticulin in patients with immune thrombocytopenic purpura. J Support Oncol. 2007;5(4):80-81.
43. Mansoor N, Saleh JBB, Oliver Meyer, Henrik Frederiksen, Diane Johnni, Manuel Aivado, Andres Brainsky. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag paper presented at: 51st ASH Annual MeetingDecember 5, 2009; Hall E (Ernest N. Morial Convention Center).
44. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100(10):3457-3469.
45. Will B, Kawahara M, Luciano JP, et al. Effect of the non-peptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899-3908.
46. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11): 4607-4616.